NASDAQ:ATHA
Athira Pharma, Inc. Stock News
$2.52
-0.190 (-7.01%)
At Close: May 17, 2024
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Athira Pharma, Inc. (ATHA) on Behalf of Investors
03:43pm, Monday, 21'st Jun 2021
BENSALEM, Pa.--(BUSINESS WIRE)---- $ATHA #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ: ATHA) inv
Implied Volatility Surging for Athira Pharma (ATHA) Stock Options
09:47am, Monday, 21'st Jun 2021
Investors need to pay close attention to Athira Pharma (ATHA) stock based on the movements in the options market lately.
Ademi LLP Investigates Claims of Securities Fraud against Athira Pharma, Inc.
06:00am, Monday, 21'st Jun 2021
MILWAUKEE, June 21, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Athira (NASDAQ: ATHA). The investigation results from inaccurate statements Athira may ha
LOS ANGELES--(BUSINESS WIRE)---- $ATHA #ATHA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Athira Pharma, Inc.
Why Athira Pharma Crashed Today
05:56pm, Friday, 18'th Jun 2021
There was a big shakeup in the biotech's C-suite.
Washington State University to review claims of research misconduct
01:09pm, Friday, 18'th Jun 2021
PULLMAN, Wash., June 18, 2021 /PRNewswire/ -- Washington State University announced today that it has undertaken a review of claims of potential research misconduct involving research conducted by L
Wolf Popper LLP Announces Investigation on Behalf of Purchasers of Athira Pharma, Inc. (ATHA) Common Stock
01:05pm, Friday, 18'th Jun 2021
New York, New York--(Newsfile Corp. - June 18, 2021) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Athira Pharma, Inc. (NASDAQ: ATHA) common stock.Ath
Berman Tabacco Investigates Potential Securities Claims Against Athira Pharma, Inc. (ATHA)
12:29pm, Friday, 18'th Jun 2021
Boston, Massachusetts--(Newsfile Corp. - June 18, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential violations of the federal securities laws by Athira P
Athira Pharma Stock Plummets After CEO Placed On Temporary Leave
06:33am, Friday, 18'th Jun 2021
Athira Pharma Inc (NASDAQ: ATHA) CEO Leen Kawas has been placed on temporary leave until the company completes a review “stemming from doctoral research Dr. Kawas conducted while at Washington St
ATHA Stock Price Falls Over 25% Pre-Market: Why It Happened
06:05am, Friday, 18'th Jun 2021
The stock price of Athira Pharma Inc (NASDAQ: ATHA) fell by over 25% pre-market. This is why it happened.
Athira Pharma CEO placed on leave, shares plummet
07:53pm, Thursday, 17'th Jun 2021
Athira Pharma CEO Leen Kawas has been placed on temporary leave until the Seattle area biotechnology company completes a review “stemming from doctoral research Dr.
Athira Pharma Chief Operating Officer, Mark Litton, Assumes Day-to-Day Leadership Responsibilities of Company
05:00pm, Thursday, 17'th Jun 2021
Leen Kawas Placed on Temporary Leave Pending Board Review of Actions Stemming from Doctoral Research while at Washington State University Leen Kawas Placed on Temporary Leave Pending Board Review of A
Athira Pharma to Present at Upcoming Investor Conferences
07:00am, Wednesday, 09'th Jun 2021
– JMP Securities Life Sciences Conference
Approval of Biogen's drug for Alzheimer's disease may ease path for others such as Athira Pharma
07:46pm, Monday, 07'th Jun 2021
The approval on Monday of the first new drug for Alzheimer's disease in nearly two decades — Biogen's aducanumab — helps shine a light on a path forward for other companies developing Alzheimer's
Athira Pharma Reports First Quarter 2021 Financial Results and Provides Business Highlights
04:02pm, Thursday, 13'th May 2021
-Phase 2 trial initiation for Parkinson's disease dementia program and IND submission for neuropsychiatric program planned by end of 2021-
